QUINTESSENTIAL-2 Study Introduction Brochure
2024-11-01Read more
QUINTESSENTIAL-2
A Phase 3 Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-Exposed Multiple Myeloma
Links
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.